Background and Purpose-Cerebral small vessel disease (SVD) is a frequent pathology in aging and contributor to the development of dementia. Plasma Aβ (amyloid β) levels may be useful as early biomarker, but the role of plasma Aβ in SVD remains to be elucidated. We investigated the association of plasma Aβ levels with severity and progression of SVD markers. Methods-We studied 487 participants from the RUN DMC study (Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort) of whom 258 participants underwent 3 MRI assessments during 9 years. We determined baseline plasma Aβ38, Aβ40, and Aβ42 levels using ELISAs. We longitudinally assessed volume of white matter hyperintensities semiautomatically and manually rated lacunes and microbleeds. We analyzed associations between plasma Aβ and SVD markers by ANCOVA adjusted for age, sex, and hypertension. Results-Cross-sectionally, plasma Aβ40 levels were elevated in participants with microbleeds (mean, 205.4 C erebral small vessel disease (SVD) is frequently seen on neuroimaging of elderly as white matter hyperintensities (WMH), lacunes, and microbleeds 1 and is recognized as the most important vascular contributor to the development of dementia.
C erebral small vessel disease (SVD) is frequently seen on neuroimaging of elderly as white matter hyperintensities (WMH), lacunes, and microbleeds 1 and is recognized as the most important vascular contributor to the development of dementia. 2, 3 Hypertensive arteriopathy and cerebral amyloid angiopathy (CAA) are the most common causes of SVD, 4 which are distinguished based on both the localization of the lesions and the distribution of neuroimaging characteristics, that is, whereas CAA predominantly affects cortical arteries and hence is characterized by lobar microbleeds, hypertensive arteriopathy typically affects small perforating end arteries in deep brain areas and is characterized by deep microbleeds. [5] [6] [7] [8] Along with traditional vascular risk factors, such as hypertension, Aβ (amyloid β) has emerged as contributor to SVD. Aβ has previously been associated with Alzheimer disease and CAA, albeit in different forms. In Alzheimer disease, Aβ accumulates in the brain to form amyloid plaques, predominantly composed of Aβ42 peptides. This is in contrast to CAA in which Aβ accumulates in the blood vessels, mostly composed of Aβ40 peptides. Several cross-sectional studies have suggested a role for circulating Aβ in SVD, reporting elevated plasma Aβ levels in participants with SVD. [9] [10] [11] [12] Prospective studies would help describe the associations between Aβ levels and SVD over time. One longitudinal study reported associations between plasma Aβ levels and WMH progression over time, although they did not find any cross-sectional associations. 13 Recent studies reported associations between plasma Aβ and hypertension, 10, 12, 14, 15 suggesting that these pathogeneses might interact. It remains to be investigated whether plasma Aβ levels are differentially associated with CAA or hypertensive SVD.
In this study, we investigated the association of baseline levels of plasma Aβ38, Aβ40, and Aβ42 peptides with both severity and progression of SVD markers, independent of hypertension. To assess whether plasma Aβ should be considered either a general SVD marker or specific for CAA, we examined Aβ levels by distribution of microbleeds.
Materials and Methods

Study Population
The RUN DMC study (Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort) is a prospective cohort study of 503 nondemented elderly with SVD, which investigates risk factors and clinical consequences of SVD. The detailed study protocol, including the inclusion and exclusion criteria, has been published previously. 16 In short, all consecutive patients referred to the Neurology Department who underwent diagnostic neuroimaging were selected for participation. Inclusion criteria were age between 50 and 85 years and SVD on neuroimaging. SVD was defined as the presence of any WMH or lacunes of presumed vascular origin on brain imaging. 17 Of 503 participants, 12 were excluded based on quality of plasma analyses: 5 participants because their Aβ levels for at least 1 of 3 Aβ peptides were below detection limits and 7 participants because the coefficients of variation for Aβ measures were >10%. Four participants were additionally excluded because of insufficient scan quality, yielding a final sample of 487 participants for the present study. Of these, 258 participants underwent repeated MRI assessment at 3 time points (baseline in 2006, first follow-up in 2011, and second followup in 2015) and could be included for longitudinal analyses. The Medical Review Ethics Committee of the region Arnhem-Nijmegen approved the study, and all participants gave written informed consent. The data that support the findings of this study are available from the corresponding author on request.
Plasma Analyses
We collected blood samples from all participants at baseline in 2006. EDTA plasma was separated from whole blood samples (10 mL blood with EDTA acting as anticoagulant) by routine methods. These samples were stored at −80°C and were only thawed immediately before Aβ quantification. We determined plasma levels of Aβ1 to 38, Aβ1 to 40, and Aβ1 to 42 isoforms (hereafter called Aβ38, Aβ40, and Aβ42) by ELISA (EUROIMMUN AG, Lübeck, Germany). No samples needed further dilution. Details on the assay procedure have been described earlier. 18 The operators were trained with a familiarization panel immunosorbent assay (ELISA) to get acquainted with the assay protocol and sample manipulation.
Neuroimaging Protocols
Images were acquired at 3 time points on 1.5-Tesla MRI (Magnetom Sonata; 2006: Siemens; and Magnetom Avanto; 2011 and 2015: Siemens) and included the following whole brain scans: T1-weighted 3-dimensional magnetization-prepared rapid gradient-echo, fluid attenuation inversion recovery, and T2*-weighted gradient echo sequence. Full acquisition details have been described previously. 16, 19 
SVD Markers
We assessed gray matter, white matter, and cerebrospinal fluid volumes using SPM12 (http://www.fil.ion.ucl.ac.uk/spm/) unified segmentation routines on the T1 magnetization-prepared rapid gradient-echo images corrected for WMH, as has been described in detail elsewhere. 19 We calculated intracranial volume by adding gray matter, white matter, and cerebrospinal fluid volumes.
WMH volumes were calculated by a semiautomatic WMH segmentation method, which has been described previously. 20 Segmentations were visually checked for segmentation errors by 1 trained rater, blinded for clinical data. WMH volumes were corrected for interscan differences in intracranial volume and then normalized to baseline intracranial volume. Because of its easy-to-use applicability, we additionally used a modified Fazekas scale to categorize WMH severity at baseline (mild, 0-1; moderate to severe, 2-3). 21 Both number and location of lacunes and microbleeds were rated manually on fluid attenuation inversion recovery/T1-weighted scans and T2*-weighted MRI scans according to the STRIVE (Standards for Reporting Vascular Changes on Neuroimaging) criteria 1 by 2 trained raters blinded for clinical data. Intrarater and interrater agreement was good (weighted κ, 0.87 and 0.95, respectively, for lacunes and 0.85 and 0.86 for microbleeds). 22 We also assessed the distribution of microbleeds, distinguishing lobar from deep microbleeds because lobar microbleeds are considered a hallmark of CAA, and deep or infratentorial microbleeds are hypothesized to result from hypertensive or atherosclerotic microangiopathy. [5] [6] [7] Incidence was expressed as the number of participants with any new microbleeds or lacunes at 9-year follow-up. Baseline and follow-up scans were checked side by side to verify incidence of microbleeds or lacunes.
Vascular Risk Factors
We assessed presence of hypertension, smoking, alcohol use, diabetes mellitus, and hypercholesterolemia at baseline by standardized questionnaires, as described previously. 16 We defined hypertension as the use of antihypertensive agents and systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg. 16 
Statistical Analysis
We assessed associations between plasma Aβ38, Aβ40, and Aβ42 levels and SVD markers by 1-way ANOVA, followed by a Bonferroni correction to correct for multiple comparisons. In cross-sectional analyses, we examined differences in plasma Aβ levels for participants with or without microbleeds or lacunes at baseline. In longitudinal analyses, we assessed differences in plasma Aβ levels for participants with or without incident microbleeds or lacunes during follow-up. We used linear regression analyses to examine associations between plasma Aβ levels and both WMH severity at baseline and WMH progression over time.
We used 4 models to investigate the associations between plasma Aβ levels and SVD markers: model 1, unadjusted; model 2, adjusted for age and sex. In model 3, we additionally adjusted for hypertension to examine whether the associations between plasma Aβ levels and SVD markers were independent of hypertension status. In model 4, we additionally adjusted for total brain volume or atrophy to examine whether the associations were independent of neurodegeneration. In analyses on longitudinal data, we also adjusted for follow-up duration and baseline severity of SVD in models 2, 3, and 4.
We additionally analyzed the associations between the ratios of plasma Aβ38/Aβ40, Aβ38/Aβ42, and Aβ42/Aβ40 and SVD markers because ratios might enhance our understanding of underlying mechanisms. To further investigate the role of hypertension, we investigated whether plasma Aβ levels were associated with hypertension status, by 1-way ANOVA followed by Bonferroni correction.
To quantify the strength of the associations between plasma Aβ levels and SVD markers, we analyzed Aβ levels in quintiles of their distribution and tested continuous linear trend per stratum. We analyzed odds ratios (ORs) of presence of microbleeds and lacunes by quintiles of Aβ using logistic regression analyses, adjusted for age and sex. We calculated WMH volumes by quintiles of Aβ levels and displayed median, 25th, and 75th percentile values as box and lower and upper adjacent values as whiskers.
Stroke
April 2018
To assess whether plasma Aβ should be considered either a general SVD marker or a specific marker for CAA, we also analyzed the relation between plasma Aβ levels and microbleeds, stratified by their location (ie, lobar versus deep or infratentorial) by 1-way ANOVA, followed by a Bonferroni correction.
Statistical analyses were performed using SPSS Statistics, version 20.
Results
Demographics, imaging characteristics, and plasma Aβ levels of the study population are shown in Table 1 . At baseline, 81 participants (16.6%) had microbleeds, 132 (27.1%) had lacunes, and 163 (33.5%) had moderate-to-severe WMH. We observed incident microbleeds in 49 participants (19.0%), incident lacunes in 62 (24.0%), and WMH progression in 34 participants (13.2%) during the follow-up of almost 9 years. Compared with participants who completed follow-up (n=258), those lost to follow-up were older, more often had hypertension or diabetes mellitus, and had more severe SVD characteristics at baseline ( Table I in the online-only Data Supplement).
Plasma Aβ38 and Aβ40 levels, but not Aβ42 levels, were elevated in participants with microbleeds or lacunes, although only the associations with Aβ40 remained significant after adjustments for age, sex, hypertension, and total brain volume ( Table 2) . Additional analyses separating participants with 1 versus >1 microbleed or lacunes revealed similar results (data not shown). A similar pattern was observed for WMH severity: plasma Aβ38 and Aβ40 levels were positively associated with WMH volume (Table 2) . Additional adjustments did not change these associations. Higher Aβ38/Aβ42 ratios and lower Aβ42/Aβ40 ratios were observed in participants with presence of SVD markers, except for the association between Aβ38/Aβ42 ratios and WMH, but the significance of these associations was lost after adjustment for age, sex, and hypertension (Table II in the online-only Data Supplement). Plasma Aβ38, Aβ40, and Aβ42 levels were elevated in participants with hypertension (Table III in the online-only Data Supplement). Figure 1 illustrates a linear increase in the prevalence of microbleeds, lacunes, and WMH volume with higher plasma Aβ40 quintiles (P trend, ≤0.001) but not with Aβ38 or Aβ42 quintiles. Participants with the highest quintile of plasma Aβ40 levels had both higher risk of microbleeds (OR, 3.3; 95% confidence interval [CI], 1.5-7.3; P=0.003 unadjusted; OR, 2.2; 95% CI, 0.95-5.0; P=0.066 age and sex adjusted) and higher risk of lacunes (OR, 3.5; 95% CI, 1.7-6.9; P<0.001 unadjusted; OR, 2.2; 95% CI, 1.1-4.6; P=0.029 age and sex adjusted). WMH volume was also higher in the highest quintile of plasma Aβ40 (median, 7.2 mL) compared with the lowest quintile (median, 1.9 mL).
Longitudinally, plasma Aβ40 levels were elevated in participants with incident lacunes and were positively associated with WMH progression, although these associations were no longer significant after additional adjustments (Table 2) . Plasma Aβ38 levels were elevated in participants with incident lacunes during follow-up, and plasma Aβ42 levels were elevated in participants with incident microbleeds (Table 2 ). These associations remained significant after additional adjustments for age, sex, follow-up duration, hypertension, total brain atrophy, and presence of SVD at baseline.
Elevated plasma Aβ40 levels were associated with higher odds of incident lacunes (P trend, 0.002; highest quintile OR, 3.0; 95% CI, 1.2-7.5; P=0.016 unadjusted; OR, 2.5; 95% CI, 0.97-6.3; P=0.058 adjusted) and WMH progression (highest quintile median, 2.3 mL; lowest quintile median, 1.3 mL; P=0.006) during the follow-up (Figure 2 ). Elevated plasma Aβ38 levels were associated with higher odds of incident lacunes (P trend, 0.045; highest quintile OR, 2.9; 95% CI, 1.2-7.3; P=0.022 unadjusted; OR, 2.5; 95% CI, 0.98-6.4; P=0.054 adjusted) and elevated plasma Aβ42 levels with higher odds of incident microbleeds (P trend, 0.041; highest quintile OR, 2.2; 95% CI, 0.78-5.9; P=0.140 unadjusted; OR, 2.2; 95% CI, 0.76-6.2; P=0.146 adjusted).
Additional analyses on plasma Aβ levels by spatial distribution of microbleeds (Table 3 ) revealed significantly elevated plasma Aβ40 levels in participants with both lobar and deep microbleeds (n=17). This was not found for plasma Aβ38 and Aβ42 levels. 
Discussion
Our study shows that elevated plasma Aβ levels were associated with neuroimaging markers of SVD, including microbleeds, lacunes, and WMH cross-sectionally and with progression of SVD longitudinally during a followup of almost 9 years. These findings suggest a relationship between Aβ pathology and the development and progression of SVD. Associations between plasma Aβ levels and presence and progression of SVD markers. Plasma Aβ levels (mean±SD in pg/mL) for participants without vs with microbleeds or lacunes at baseline (top, n=487) and for participants without vs with incident microbleeds or lacunes during the course of 9 years (bottom, n=258). Statistical differences are analyzed by 1-way ANOVA, followed by a Bonferroni correction. Associations between plasma Aβ levels and WMH are analyzed by linear regression analyses; displayed as unadjusted standardized β with 95% CIs. CI indicates confidence interval; SVD, small vessel disease; and WMH, white matter hyperintensities.
* 
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Our cross-sectional findings that plasma Aβ levels are elevated in participants with SVD are in line with results from previous cross-sectional studies. The Swedish BioFINDER study (Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably) reported associations between elevated plasma Aβ40 and Aβ42 levels and WMH and microbleeds, 10 and the ADNI study (Alzheimer's Disease Neuroimaging Initiative) reported elevated Aβ40 levels in participants with lacunar infarctions. 12 Another study in elderly with CAA, Alzheimer disease, and mild cognitive impairment reported associations between elevated plasma Aβ40 levels and increased WMH and lacunes in all groups. 9 In the populationbased Rotterdam Scan Study, elevated plasma Aβ40 and Aβ42 levels were associated with the extent of WMH and the presence of lacunes in APOE ε4 carriers only. 11 Unfortunately, we do not have data on APOE genotype for our participants. More recently, associations between elevated plasma Aβ38, Aβ40, and Aβ42 levels and markers of SVD have been reported in 2 subsamples of the same population-based study. 23 Our results showing elevated plasma Aβ levels in participants with SVD strengthen the evidence for an association between plasma Aβ and SVD cross-sectionally.
The longitudinal design of our study enabled us to elaborate on the directionality of the associations between plasma Aβ levels and cerebrovascular pathology. In our study, progression of WMH and incident microbleeds and lacunes were associated with elevated plasma Aβ levels of ≥1 of the peptides. In contrast, the Three-City Dijon Study showed that decreased plasma Aβ40 and Aβ42 levels were associated with WMH progression over time but did not find cross-sectional associations of plasma Aβ with SVD markers. 13 Discrepancies in these results might be explained by the different study populations with variation in SVD burden, different assay designs, or how the analysis of the samples was done. Especially, the multicenter design might have complicated longitudinal SVD assessment. 24 Interestingly, in our study, associations were different for different Aβ peptides: elevated Aβ42 levels were associated with incident microbleeds, whereas elevated Aβ38 and Aβ40 levels were associated with WMH progression and incident lacunes. This might be explained by the characteristics of the different Aβ peptides because the Aβ42 peptide is known to have more tendency to aggregate compared with the Aβ38 and Aβ40 peptides. 25, 26 Plasma Aβ levels are expressed as mean±SD (in pg/mL) and stratified by distribution of microbleeds. Statistical differences in plasma Aβ levels vs group without microbleeds, analyzed by 1-way ANOVA followed by Bonferroni correction.
*P<0.05 unadjusted.
Aβ42 in the media of arterioles 27 might weaken the vessel walls and ultimately lead to hemorrhages, 28 although experimental studies would be required to investigate the underlying mechanisms. Altogether, our findings that elevated plasma Aβ levels were not only associated with severity of SVD crosssectionally but also predicted the progression of SVD over time suggest that Aβ pathology-either neurodegeneration or CAA-might contribute to the development and progression of SVD.
Several mechanisms could explain the associations between plasma Aβ levels and SVD. First, plasma Aβ might enhance endothelium-dependent vasoconstriction, leading to cerebral hypoperfusion, which in turn might result in WMH and lacunes. [29] [30] [31] Second, an inverse relation could also explain our findings, that is, that cerebral hypoperfusion, or reduced cerebral blood flow, promotes overproduction of Aβ and its secretion into the circulation. 32 Our findings showing associations between plasma Aβ levels and progression of SVD markers over time support the first mechanism. Third, a relative overproduction of Aβ might lead to enhanced Aβ accumulation in the media of arterioles, 27 weakening the vessel walls and leading to microbleeds. Fourth, SVD might affect plasma amyloid levels through impairment in perivascular clearance, 33 leading to vascular amyloid deposits and decreased plasma Aβ levels. Because we found elevated plasma Aβ levels in participants with SVD, we consider the latter hypothesis less likely. Finally, the reported associations between plasma Aβ and SVD might also be explained by mixed age-related pathologies, that is, SVD might interact with Alzheimer type neurodegeneration. This hypothesis has been supported by previous studies reporting the presence of WMH in patients with Alzheimer disease, 34, 35 although our findings that associations between plasma Aβ levels and SVD markers were independent of markers for neurodegeneration attenuate this hypothesis.
Our findings indicate that plasma Aβ levels are elevated in participants with hypertension (Table III in the online-only  Data Supplement) , which, in turn, is associated with SVD markers (data not shown). This association between hypertension and plasma Aβ is also reported in previous studies. 10, 12, 14, 15 In our analyses, we adjusted for hypertension to confirm that the associations between plasma Aβ levels and SVD markers were independent of hypertension. In future, it would be interesting to study the interactions between blood pressure, plasma Aβ levels, and cerebrovascular pathology in more detail.
Additional analyses on plasma Aβ levels by distribution of microbleeds showed no clear distinction in plasma Aβ levels between deep versus lobar microbleeds, although analyses might have been underpowered. Together with the associations found between plasma Aβ levels and WMH and lacunes, these results suggest that plasma Aβ might be a general cerebrovascular disease marker rather than specific for CAA.
Major strengths of this study include the large number of elderly participants with SVD in whom both plasma Aβ levels and neuroimaging were assessed and the longitudinal design of the study with a long follow-up duration. The long followup duration enabled us to study progression of SVD makers, including WMH, lacunes, and microbleeds over the course of almost a decade. Furthermore, assessments of SVD neuroimaging markers and Aβ levels were performed blinded to clinical data, limiting the risk of bias. Finally, our study has high external validity for patients with SVD in a general neurology clinic.
Several limitations deserve consideration. First, because we only collected plasma samples at baseline, we were not able to perform repeated plasma Aβ measurements. As a consequence, we could not assess the influence of changes in plasma Aβ levels over time on progression of SVD markers. Second, we do not have information on APOE genotype, which precluded us from studying the interaction between APOE status, plasma Aβ levels, and SVD markers. Third, attrition bias might have led to an underestimation of the effects. Because of the long-term follow-up of our study, a proportion of the participants was unable to complete the entire follow-up, which may have reduced power in analyses on progression of SVD markers over time because those lost to follow-up had more severe SVD already at baseline (Table I in the onlineonly Data Supplement).
Summary
In summary, we report associations between plasma Aβ levels and neuroimaging markers of SVD, both cross-sectional on severity of SVD at baseline and longitudinal on progression of SVD over time. These findings suggest a relationship between Aβ and vascular disease. Plasma Aβ levels might thereby serve as measure for identifying individuals with increased risk for progression of SVD.
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